REGN88

Phase 2Biologic

Regeneron

REGN88 is one of 27 biologic programs targeting Juvenile Idiopathic Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Juvenile Idiopathic ArthritisRecruiting

Juvenile Idiopathic ArthritisPhase 2

Recruiting

Competition

Competitive Landscape

27 competitors in Juvenile Idiopathic Arthritis

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

7 2

Arava

Sanofi

Approved

1 3

Azulfidine

Pfizer

Approved

1 4

Aleve

Medrol

Humira

RRanbaxy Laboratories Limited

Approved

3 7

Celebrex

PPhiladelphia Eye Associates

Approved

1 8

Anjeso

Boehringer Ingelheim

Approved

—9

Decadron

AAspen Global Incorporated

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Juvenile Idiopathic Arthritis

NCT02991469

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

Completed· Regeneron logo

Regeneron·Phase 1·NCT01011959·60 enrolled

A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

Completed· Regeneron logo

Regeneron·Phase 1·NCT01026519·32 enrolled

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

Completed· Regeneron logo

Regeneron·Phase 1·NCT01055899·15 enrolled

Juvenile Idiopathic Arthritis1 trial

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT02991469·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for REGN88. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN88 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN88. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN88

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Juvenile Idiopathic Arthritis1 trial

References

Drug Info

Quick Facts

Related News